PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo
2011 | 6 | 1 | 64-75
Tytuł artykułu

The polycystic ovary syndrome (pcos) status and cardiovascular risk in young women

Treść / Zawartość
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
The study investigated the presence of early vascular damage and chronic inflammation, and their relationships with hormonal and metabolic parameters in 45 young women with PCOS in comparison with thirty-two healthy age-matched controls. Hormonal and metabolic profiles, high sensitivity C-reactive protein (hsCRP), tumoral necrosis factor-alpha (TNF-α), endothelin-1 (ET-1), brachial flow-mediated vasodilation (FMD) and carotid intima-media thickness (CIMT) were determined in both groups. Compared with the controls, women with PCOS had significantly lower FMD and respectively higher ET-1 levels (p=0.001). No differences were observed between the groups in terms of CIMT or inflammatory markers. In the PCOS group, ET-1 levels were significantly correlated with only testosterone concentrations (r = 0.31, p = 0.037), whereas the hsCRP levels were independently predicted only by body mass index (BMI). Within the total group, the PCOS status was the sole significant predictor of ET-1 levels and the only independent predictor of FMD. In conclusion, there is evidence of endothelial dysfunction associated with increased levels of androgen hormones in young women with PCOS. The combination of endothelial dysfunction and coexistent obesity promoting inflammation contributes to the progression of atherogenesis in PCOS. The PCOS status should be regarded as a predictor marker of cardiovascular risk, along with well-known cardiovascular risk factors.
Wydawca
Czasopismo
Rocznik
Tom
6
Numer
1
Strony
64-75
Opis fizyczny
Daty
wydano
2011-02-01
online
2010-12-16
Twórcy
autor
  • Department of Endocrinology, University of Medicine and Pharmacy, 400349, Louis Pasteur, Cluj-Napoca, Romania , ioanamanaila@yahoo.com
  • Department of Endocrinology, University of Medicine and Pharmacy, 400349, Louis Pasteur, Cluj-Napoca, Romania
autor
  • Department of Internal Medicine-Cardiology, University of Medicine and Pharmacy, 400006, Clinicilor, Cluj-Napoca, Romania
  • Department of Physiology, University of Medicine and Pharmacy, 400349, Louis Pasteur, Cluj-Napoca, Romania
  • Clinic of Endocrinology, County Emergency Hospital, 400349, Louis Pasteur Cluj-Napoca, Romania
  • Clinic of Endocrinology, County Emergency Hospital, 400349, Louis Pasteur Cluj-Napoca, Romania
autor
  • Department of Obstetrics and Gynecology, University of Medicine and Pharmacy, 400124, Cluj-Napoca, Romania
autor
  • Department of Surgery, University of Medicine and Pharmacy, 19-21 Croitorilor, 3400, Cluj-Napoca, Romania
  • Department of Endocrinology, University of Medicine and Pharmacy, 400349, Louis Pasteur, Cluj-Napoca, Romania
Bibliografia
  • [1] Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ, Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society, Fertil. Steril., 2009, 92, 1966–1982 http://dx.doi.org/10.1016/j.fertnstert.2008.09.018[Crossref]
  • [2] Glueck CJ, Morrison JA, Goldenberg N, Wang P, Coronary heart disease risk factors in adult premenopausal white women with polycystic ovary syndrome compared with a healthy female population, Metabolism 2009, 58, 714–721 http://dx.doi.org/10.1016/j.metabol.2009.02.005[Crossref][WoS]
  • [3] Diamanti-Kandarakis E., Spina G., Kouli C., Migdalis I., Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy, J. Clin. Endocrinol. Metab., 2001, 86, 4666–4673 http://dx.doi.org/10.1210/jc.86.10.4666
  • [4] Orio F. Jr., Palomba S., Cascella T., De Simone B., Di Biase S., Russo T., Labella D., et al., Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2004, 89,4588–4593 http://dx.doi.org/10.1210/jc.2003-031867[Crossref]
  • [5] Orio F, Jr., Palomba S., Cascella T., De Simone B., Manguso F., Savastano S., et al., Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study, J. Clin. Endocrinol. Metab., 2005, 90, 6072–6076 http://dx.doi.org/10.1210/jc.2005-0965
  • [6] Moran L.J., Hutchison S.K., Meyer C., Zoungas S., Teede HJ., A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome, Clin. Sci. (Lond), 2009, 116,761–770 http://dx.doi.org/10.1042/CS20080218[Crossref]
  • [7] Kravariti M., Naka K.K., Kalantaridou S.N., Kazakos N., Katsouras C.S., Makrigiannakis A., et al., Predictors of endothelial dysfunction in young women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 5088–5095 http://dx.doi.org/10.1210/jc.2005-0151[Crossref]
  • [8] Arikan S., Akay H., Bahceci M., Tuzcu A., Gokalp D., The evaluation of endothelial function with flow-mediated dilatation and carotid intima media thickness in young nonobese polycystic ovary syndrome patients; existence of insulin resistance alone may not represent an adequate condition for deterioration of endothelial function, Fertil. Steril., 2009, 91,450–455 http://dx.doi.org/10.1016/j.fertnstert.2007.11.057[WoS][Crossref]
  • [9] Diamanti-Kandarakis E., Alexandraki K., Protogerou A., Piperi C., Papamichael C, Aessopos A., et al., Metformin administration improves endothelial function in women with polycystic ovary syndrome, Eur. J. Endocrinol., 2005, 152,749–756 http://dx.doi.org/10.1530/eje.1.01910[Crossref]
  • [10] Diamanti-Kandarakis E., Alexandraki K., Piperi C., Protogerou A., Katsikis I., Paterakis T., et al., Inflammatory and endothelial markers in women with polycystic ovary syndrome, Eur. J. Clin. Invest., 2006, 36, 691–697 http://dx.doi.org/10.1111/j.1365-2362.2006.01712.x[Crossref]
  • [11] Tarkun I., Arslan B.C., Canturk Z., Turemen E., Sahin T., Duman C., Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation, J. Clin. Endocrinol. Metab., 2004, 89, 5592–5596 http://dx.doi.org/10.1210/jc.2004-0751[Crossref]
  • [12] Brinkworth G.D., Noakes M., Moran L.J., Norman R., Clifton P.M., Flow-mediated dilatation in overweight and obese women with polycystic ovary syndrome, BJOG, 2006, 113, 1308–1314 http://dx.doi.org/10.1111/j.1471-0528.2006.01090.x[Crossref]
  • [13] Talbott E.O., Guzick D.S., Sutton-Tyrrell K., McHugh-Pemu K.P., Zborowski J.V., Remsberg K.E., Kuller L.H., Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women, Arterioscler. Thromb. Vasc. Biol., 2000, 20, 2414–2421 [Crossref]
  • [14] Vural B., Caliskan E., Turkoz E., Kilic T., Demirci A., Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome, Hum. Reprod., 2005, 20, 2409–2413 http://dx.doi.org/10.1093/humrep/dei100[Crossref]
  • [15] Costa L.O., dos Santos M.P., Oliveira M., Viana A., Low-grade chronic inflammation is not accompanied by structural arterial injury in polycystic ovary syndrome, Diabetes. Res. Clin. Pract., 2008, 81, 179–183 http://dx.doi.org/10.1016/j.diabres.2008.04.005[WoS][Crossref]
  • [16] Carmina E., Orio F., Palomba S., Longo R.A., Cascella T., Colao A., et al., Endothelial dysfunction in PCOS: role of obesity and adipose hormones, Am. J. Med., 2006, 119, 356 e351–356 http://dx.doi.org/10.1016/j.amjmed.2005.10.059[Crossref]
  • [17] Diamanti-Kandarakis E., Paterakis T., Kandarakis H.A., Indices of low-grade inflammation in polycystic ovary syndrome, Ann. N. Y. Acad. Sci., 2006, 1092, 175–186 http://dx.doi.org/10.1196/annals.1365.015[Crossref]
  • [18] Gonzalez F., Rote N.S., Minium J., Kirwan J.P., Evidence of proatherogenic inflammation in polycystic ovary syndrome, Metabolism, 2009, 58, 954–962 http://dx.doi.org/10.1016/j.metabol.2009.02.022[Crossref][WoS]
  • [19] Kaya C., Pabuccu R., Berker B., Satiroglu H., Plasma interleukin-18 levels are increased in the polycystic ovary syndrome: relationship of carotid intima-media wall thickness and cardiovascular risk factors, Fertil. Steril., 2009 [WoS]
  • [20] Mohlig M., Spranger J., Osterhoff M., Ristow M., Pfeiffer A.F., Schill T., et al., The polycystic ovary syndrome per se is not associated with increased chronic inflammation, Eur. J. Endocrinol., 2004, 150, 525–532 http://dx.doi.org/10.1530/eje.0.1500525[Crossref]
  • [21] Olszanecka-Glinianowicz M., Banas M., Zahorska-Markiewicz B., Janowska J., Kocelak P., Madej P., Klimek K., Is the polycystic ovary syndrome associated with chronic inflammation per se?, Eur. J. Obstet. Gynecol. Reprod. Biol., 2007, 133, 197–202 http://dx.doi.org/10.1016/j.ejogrb.2006.10.037[Crossref]
  • [22] Azziz R., Carmina E., Dewailly D., Diamanti-Kandarakis E., Escobar-Morreale H.F., Futterweit W., et al., Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline, J. Clin. Endocrinol. Metab., 2006, 91, 4237–4245 http://dx.doi.org/10.1210/jc.2006-0178[Crossref]
  • [23] Rosei EA, Assessment of preclinical target organ damage in hypertension: carotid intima-media thickness and plaque, Blood. Press., 2003, 12, 185–186
  • [24] Dagre A., Lekakis J., Mihas C., Protogerou A., Thalassinou L., Tryfonopoulos D., et al., Association of dehydroepiandrosterone-sulfate with endothelial function in young women with polycystic ovary syndrome, Eur. J. Endocrinol., 2006, 154, 883–890 http://dx.doi.org/10.1530/eje.1.02153[Crossref]
  • [25] Paradisi G., Steinberg H.O., Hempfling A., Cronin J., Hook G., Shepard M.K., Baron A.D., Polycystic ovary syndrome is associated with endothelial dysfunction, Circulation, 2001, 103, 1410–1415 [Crossref]
  • [26] Vryonidou A., Papatheodorou A., Tavridou A., Terzi T., Loi V., Vatalas I.A., et al., Association of hyperandrogenemic and metabolic phenotype with carotid intima-media thickness in young women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 2740–2746 http://dx.doi.org/10.1210/jc.2004-2363[Crossref]
  • [27] Meyer C., McGrath B.P., Cameron J., Kotsopoulos D., Teede H.J., Vascular dysfunction and metabolic parameters in polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 4630–4635. http://dx.doi.org/10.1210/jc.2004-1487[Crossref]
  • [28] Higashiura K., Mathur R.S., Halushka P.V., Gender-related differences in androgen regulation of thromboxane A2 receptors in rat aortic smoothmuscle cells, J. Cardiovasc. Pharmacol., 1997, 29, 311–315. http://dx.doi.org/10.1097/00005344-199703000-00002[Crossref]
  • [29] Chou T.M., Sudhir K., Hutchison S.J., Ko E., Amidon T.M., Collins P., et al., Testosterone induces dilation of canine coronary conductance and resistance arteries in vivo, Circulation, 1996, 94, 2614–2619. [Crossref]
  • [30] Zitzmann M., Brune M., Kornmann B., Gromoll J., von Eckardstein S., von Eckardstein A., et al., The CAG repeat polymorphism in the AR gene affects high density lipoprotein cholesterol and arterial vasoreactivity, J. Clin. Endocrinol. Metab., 2001, 86, 4867–4873. http://dx.doi.org/10.1210/jc.86.10.4867[Crossref]
  • [31] Rodriguez-Gonzalez G., Ramirez-Moreno R., Perez P., Bilbao C., Lopez-Rios L., Diaz-Chico J.C., The GGN and CAG repeat polymorphisms in the exon-1 of the androgen receptor gene are, respectively, associated with insulin resistance in men and with dyslipidemia in women, J. Steroid. Biochem. Mol. Biol., 2009, 113, 202–208. http://dx.doi.org/10.1016/j.jsbmb.2008.12.009[WoS][Crossref]
  • [32] Van Nieuwerburgh F., Stoop D., Cabri P., Dhont M., Deforce D., De Sutter P., Shorter CAG repeats in the androgen receptor gene may enhance hyperandrogenicity in polycystic ovary syndrome, Gynecol. Endocrinol., 2008, 24, 669–673. http://dx.doi.org/10.1080/09513590802342841[Crossref]
  • [33] Mather K.J., Verma S., Corenblum B., Anderson T.J., Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2000, 85, 1851–1856. http://dx.doi.org/10.1210/jc.85.5.1851[Crossref]
  • [34] Meyer C., McGrath B.P., Teede H.J., Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease, J. Clin. Endocrinol. Metab., 2005, 90, 5711–5716. http://dx.doi.org/10.1210/jc.2005-0011[Crossref]
  • [35] Shroff R., Kerchner A., Maifeld M., Van Beek E.J., Jagasia D., Dokras A., Young obese women with polycystic ovary syndrome have evidence of early coronary atherosclerosis, J. Clin. Endocrinol. Metab., 2007, 92, 4609–4614. http://dx.doi.org/10.1210/jc.2007-1343[Crossref]
  • [36] Capoglu I. Erdem F., Uyanik A., Turhan H., Serum levels of resistin and hsCRP in women with PCOS, Cent. Eur. J. Med., 2009.
  • [37] Talbott E.O., Zborowski J.V., Boudreaux M.Y., McHugh-Pemu K.P., Sutton-Tyrrell K., Guzick D.S., The relationship between C-reactive protein and carotid intima-media wall thickness in middle-aged women with polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2004, 89, 6061–6067. http://dx.doi.org/10.1210/jc.2003-032110[Crossref]
  • [38] Orio F, Jr., Palomba S., Cascella T., Di Biase S., Manguso F., Tauchmanova L., et al., The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome, J. Clin. Endocrinol. Metab., 2005, 90, 2–5. http://dx.doi.org/10.1210/jc.2004-0628[Crossref]
  • [39] Diamanti-Kandarakis E., Paterakis T., Alexandraki K., Piperi C., Aessopos A., Katsikis I., et al., Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin, Hum. Reprod., 2006, 21, 1426–1431. http://dx.doi.org/10.1093/humrep/del003[Crossref]
  • [40] Ilie I.R., Pepene C., Duncea I., Ilie R., Vascular abnormalities and low-grade chronic inflammation in women with polycystic ovary syndrome:Relationships with insulin resistance, obesity and hyperandrogenemia, Cent. Eur. J. Med., 2008, 3, 257–270. http://dx.doi.org/10.2478/s11536-008-0044-8[Crossref][WoS]
  • [41] Carmina E., Bucchieri S., Esposito A., Del Puente A, Mansueto P, Orio F, et al.,Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance, J. Clin. Endocrinol. Metab., 2007, 92, 2500–2505. http://dx.doi.org/10.1210/jc.2006-2725[WoS][Crossref]
  • [42] Puder J.J., Varga S., Kraenzlin M., De Geyter C., Keller U., Muller B., Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance, J. Clin. Endocrinol. Metab., 2005, 90, 6014–6021. http://dx.doi.org/10.1210/jc.2005-1002[Crossref]
  • [43] Cascella T., Palomba S., De Sio I., Manguso F., Giallauria F., De Simone B, et al., Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome, Hum. Reprod., 2008, 23, 153–159. http://dx.doi.org/10.1093/humrep/dem356[Crossref]
  • [44] Tosi F. D.R., Castello R., Maffeis C., Spiazzi G., Zoppini G., Muggeo M., et al., Body fat and insulin resistance independently predict increased serum C-reactive protein in hyperandrogenic women with polycystic ovary syndrome, Eur. J. Endocrinol., 2009, 161, 737–745. http://dx.doi.org/10.1530/EJE-09-0379[Crossref]
  • [45] Kelly C.C., Lyall H., Petrie J.R., Gould G.W., Connell J.M., Sattar N., Low grade chronic inflammation in women with polycystic ovarian syndrome, J. Clin. Endocrinol. Metab., 2001, 86, 2453–2455. http://dx.doi.org/10.1210/jc.86.6.2453[Crossref]
  • [46] McCrohon J.A., Jessup W., Handelsman D.J., Celermajer D.S., Androgen exposure increases human monocyte adhesion to vascular endothelium and endothelial cell expression of vascular cell adhesion molecule-1, Circulation, 1999, 99, 2317–2322. [Crossref]
  • [47] Norata G.D., Tibolla G., Seccomandi P.M., Poletti A., Catapano A.L., Dihydrotestosterone decreases tumor necrosis factor-alpha and lipopolysaccharide-induced inflammatory response in human endothelial cells, J. Clin. Endocrinol. Metab., 2006, 91, 546–554. http://dx.doi.org/10.1210/jc.2005-1664[Crossref]
  • [48] Li S., Li X., Li Y., Regulation of atherosclerotic plaque growth and stability by testosterone and its receptor via influence of inflammatory reaction, Vascul. Pharmacol., 2008, 49,14–18. http://dx.doi.org/10.1016/j.vph.2008.03.004[Crossref]
Typ dokumentu
Bibliografia
Identyfikatory
Identyfikator YADDA
bwmeta1.element.-psjd-doi-10_2478_s11536-010-0054-1
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.